ABSTRACT
INTRODUCTION
Estrogen regulates development, growth and a variety of differentiated functions of female reproductive organs of vertebrates and is a mitogen for the uterus of adult mammals, where it stimulates growth of endometrial epithelia (1-2 and references therein). The estrogen receptor is a /rans-acting transcription enhancer factor, that binds to cis -acting Estrogen Response Elements (EREs), localized in the proximity of target genes.to modulate gene expression (3) (4) (5) . Structural and functional analysis of estrogen regulated genes have revealed a common, palindromic ERE, with the consensus sequence 5'-GGTCANNNTGACC-3', that is sufficient to mediate hormone-dependent induction of transcription and that binds the estrogen receptor 'in vitro' (5, 6) . Also, it has been shown that most EREs are imperfectly palindromic, although in this case they are less efficient in mediating transcriptional regulation by the receptor and they bind weakly the receptor (7 -10) . Four members of the nuclear receptors super-family (estrogen, retinoic acid, thyroid hormone and vitamin D receptors) can activate transcription through homologs of the basic sequence GGTCA-TGACC, here named Nuclear Receptors Response Element (NRRE; [11] [12] [13] [14] [15] . Exact spacing (3 bp) between the two hexameric halves of the palyndrome is essential for estrogen receptor action, whereas it is not required by the other receptors (12; H. de Verneuil, D. Metzger and P. Chambon, personal communication). To explain the mitogenic effect of estrogen, it was assumed that this hormone regulates the expression of genes whose products control the ceD cycle. In line with this hypothesis, 17/3-estradiol was found to induce, both in rat uterus and in human breast cancer cells in culture, the expression of c-fos and c-myc proto-oncogenes (16) (17) (18) (19) (20) (21) and, more recently, of c-jun and jun-B genes (22; M.Scalona, E.Persico, L.Cicatiello, V.Sica, F.Bresciani and A.Weisz, manuscript in preparation). Induction by 17/3-estradiol ofc-fos gene expression in rat uterus is due to stimulation of transcription of this gene and is not abolished by protein synthesis inhibitors, suggesting that the receptor regulates directly c-fos gene promoter activity (23) (24) .
To understand the molecular basis of c-fos gene regulation by estrogen, the effect of the estrogen receptor on the expression of fos -CAT reporter genes containing the human c-fos gene promoter, with its 5'-flanking DNA up to 2250 bp 5' to the startsite of transcription, was analysed by transient transfection in HeLa cells. Transcription of the fos -CAT reporters is stimulated significantly by the estrogen-receptor complex only when the region of c-fos 5'-flanking DNA localized between positions -1300 and -850 is present. Sequence analysis of this region reveals the presence of a sequence corresponding to an imperfectly palindromic ERE: CGGCAGCGTGACC. overlapping with two sequences homologous to the core sequence of AP-1 transcription factor binding sites: CTGAG and GTGAC. An oligonucleotide reproducing all these elements binds 'in vitro' the estrogen receptor and AP-1-like factors and confers estrogen responsivity to an etherologous promoter. This is the first demonstration that expression of a proto-oncogene is directly controlled by the estrogen receptor and may explain how this hormone regulates the early phases of the cell cycle in responsive cells.
MATERIALS AND METHODS

Construction of reporter recombinants and DNA sequence determination
Standard DNA recombinant techniques were used (25) . pFCl-BL was constructed inserting the Hind HI-Nae I fragment from plasmid pc-fos(human)-l (26) (27) , that includes the promoter and 5'-flanking region of the human c-fos gene (from about position -2250 to position +41), into the Hind HI to Sal I (bluntended with Klenow) sites of the pBL-CAT 3 vector (28) . pFC2-BL, pFC3-BL, pFC4-BL and pFC8-BL were generated from pFCl-BL deleting the Hind m (-2250) to Nae I (-1400), Hind m to Bam HI (-720), Hind III to Sst H (-404) or Hind III to Apa I (-224) fragments respectively. pFC2(A), pFC2(C) and pFC2(D) were obtained by partial digestion of pFC2-BL with Apa I, followed by re-ligation, and lack the DNA fragment included between the Apa I sites at positions -1300 and -850 (A), -1300 and -224 (C) or -850 and -224 (D). pFOS-tk -CAT I was produced cloning the Hind III to Nae I fragment of pFC-l-BL into the Hind III to Xba I (blunt-ended) sites of pBL-CAT 2 (28) . pFOS-tk -CAT II was produced cloning the Nae I to Bam HI fragment of pFC 1 -BL into the Hind TU (bluntended) to Bam HI sites of pBL-CAT 2 and pFOS-tk -CAT H(A), II(B) and II(C) were derived from pFOS-tk -CAT II by deleting the Apa I (-1300) to Apa I (-850) region, the Apa I (-850) to Bam HI (-720) region or the Apa I (-1300) to Bam HI (-720) region respectively. pFOS-r/fc -CAT V+ and V-were constructed cloning in pBL-CAT 2 the DNA fragment located between the Apa I sites at -1300 and -850, in the natural ( + ) or the opposite (-) orientation respect to the tk promoter. pFOStk -CAT VI and VII were generated respectively by cloning the Apa I (-1300) to Pvu n (-1060) and Pvu U to Apa I (-850) fragments of pc-fos (human)-1.
The sequence of both strands of the Apa I (-1300) to Apa I ( -850) fragment of the human c-fos gene 5'-flanking DNA was determined by chain-termination DNA sequencing (29) of single stranded DNA , using Sequenase and protocols suggested by the producer of this enzyme (USB Co., Cleveland, USA).
pFOS-ERE 1 and 3 or pFOS-EREjt 1 and 3 were obtained cloning the ds oligonucleotides A or C (reported in Table III) , respectively, into the Hind HI to Sph I sites of pBL-CAT 2. pFOS-NRRE 1 and 3 or pFOS-NRRE/i 1 and 3 were obtained cloning the ds oligonucleotides D or G, respectively, into the Bam HI to Xba I sites of pBL-CAT 2. Positive clones were controlled by determinig the sequence of the inserted oligonucleotides.
Transient transfection and CAT assay For transient transfection, HeLa cells were plated on day 1 at about 10-20% confluency in DMEM (without phenol red) containing 5% FCS, pre-treated with dextran-coated charcoal to remove endogenous steroids (30) and 100 U/ml penicillin/streptomycin. On day 2, fresh medium was added and cells were transfected, using the calcium phosphate-DNA coprecipitation method (31) , with the indicated amount of reporter and expression vectors, 3 ng of/3-galactosidase expression vector pCH 110 (Pharmacia), as internal control for transfection efficiency, and carrier DNA (Bluescribe M13 + ) up to 20 ng total DNA/cell culture dish. After 12 to 16 hrs, cells were washed with medium for 30 min, before addition of fresh medium (with or without 10~8 M 17/3-estradiol as indicated) and further incubated for 24 hrs. CAT enzyme assay were performed in whole-cell extracts as described (32) , after normalization for (3-galactosidase activity (22) . Chloramphenicol acetyltransferase activity is reported as pmoles ( l4 C)chloramphenicol acetylated/hr/unit /3-galactosidase activity.
Gel retardation assay and competition experiments
HeLa cells 'whole-cell' extracts were prepared as described by Kumar and Chambon (5) in 50 mM Tris-HCl (pH 7.3 at 20°C), 600 mM KC1, 1 mM MgCl 2 , 1 mM DTT, 25% Glycerol (v/v) and protease inhibitors (2.5 /tg ea/ml of antipain, aprotinin, chymostatin, leupeptin, pepstatin and 0.5 /iM PMSF). Protein concentration in the extracts was determined with a colorimetric assay (33) .
Gel retardation assays were performed essentially as described (34) (35) . Extracts (2 to 10 ng proteins) were pre-incubated with 2 /ig (ERE probe) or with 0.5 fig (all other probes) of poly(dldC) (Pharmacia or Boehringer-Mannheim) at 0°C in a 12 /tl reaction mix containing 50 mM Tris-HCl (pH 7.3 at 20°C), 50 mM KC1, 1 mM MgCl 2 , 1 mM DTT, 25% Glycerol (v/v). After 10 min, the binding reaction was initiated by adding 10 to 20 fmoles (1 to 6x10" cpm) of [ 32 P]-5' end-labelled ds synthetic oligonucleotide probe and incubation was carried out at 20°C for 15 min. Non-denaturing PAGE was then used to separate the free from the protein-bound probe. In the competition experiments, the indicated amounts of unlabelled probes were mixed with the labelled probe (about 1 to 2x 10 4 cpm) before addition to the binding reaction. tested by transient transfection in HeLa cells. Where specified, the plasmid HEO, containing the human estrogen receptor cDNA cloned in the eucaryotic expression vector pSG5 (36) , was cotransfected, since these cells lack detectable estrogen receptor. The result of a representative transfection experiment is reported in Figure 1 excluded. Changes in chloramphenicol acetyltransferase activity were quantified by measuring the amount of acetylated chloramphenicol in all samples, after correction for changes in transfection efficiency, and a summary of the results obtained in several transfection experiments are reported in Table I . This shows that the c-fos gene promoter in pFC 1 -BL is active in HeLa cells under the conditions used for this study (compare with pBL-CAT 3), and that the estrogen-receptor complex stimulates about 5 fold the expression of the reporter gene. Interestingly, this result is in line with the observation that estrogen administration is followed by an about 4 to 6 fold activation of c-fos gene transcription in rat uterus in vivo (24) .
RESULTS
Identification
To map the location of the estrogen-inducible element(s) within the c-fos gene 5'-flanking DNA, a set of progressive 5' to 3' deletions of the fos sequence in pFCl-BL were generated, and the corresponding reporters were tested for estrogen responsivity in HeLa cells ( Figure 1 and Table I ). Removal of 5'-flanking DNA localized between positions -2250 and -1400 (plasmid pFC2-BL) has no effect on the response to estrogen (compare lanes 5 and 7), whereas deletion of the region localized between positions -1400 and -720 (plasmid pFC3-BL) reduces it significantly (compare lanes 9 and 11). A deletion to position -404 has no further effect (plasmid pFC4-BL; compare lanes 13 and 15), whereas a deletion to position -224 results in the complete loss of estrogen inducibility (plasmid pFC8-BL; compare lanes 17 and 19) . This observation is confirmed by another series of experiments, in which c-fos 5'-flanking DNA (Figure 1 top) . Activity of the tk promoter from this test gene is stimulated by the estrogen-receptor complex 3 to 4 fold (compare lanes 29 and 31 in Figure 1 bottom and see Table I ). This relatively low level of induction was reproducible and confirmed in several, independent experiments. For comparison, in Figure 1 and Table I are also reported the results obtained with the estrogen-responsive reporter pWYT-tk -CAT, containing the ERE from the X. laevis vitellogenin A2 gene (6, 37) . This test gene is also inducible by the estrogenreceptor complex under the experimental conditions used (10 to 12 fold, compare lanes 37 with 39 in Figure 1 ). When 1/xg of pVIT-rA: -CAT or 5 ng of pFOS-r* -CAT II was used, maximal stimulation was obtained with 25 to 50 ng and 250 to 500 ng of HEO respectively (data not shown), suggesting a different sensitivity to the estrogen receptor of the putative fos ERE, compared with the vitellogenin ERE. The response to HEO of the reporters containing the c-fos 5'-flanking region from position -404 to position -224 is somehow erratic and not always reproducible, is low and only weakly enhanced by 17/3-estradiol in HeLa cells (Table I) and is better seen when higher concentrations of HEO (up to 12 /ig plasmid/dish) are used. It is possible that this effect is artifactual, due to interference by Figure 2 and see Table II ). This result is confirmed with the fas DNA in the reporter pFOS-f£ -CAT II, since internal deletions that remove the -1300 to -850 region result, here also, in the loss of estrogen inducibility (see pFOS-f/t -CAT II(A) and II(C) in Table  II ). Tables  I and II) . This negative effect on promoter activity is reproducible in a large number of separate transfection experiments and is more evident when the DNA from -850 and -224 is deleted, since the basal expression decreases in this case more than 8 fold, under comparable conditions (1/ig reporter/dish, compare pFC2(D) with pFC2(C) in Table II and with pFC8-BL in Table I ). The same is true for the tk promoter, whose basal activity is reduced 2.5 to 4 fold (compare lanes 29 and 33 in Figure 1 , pFOS-flt -CAT II with pBL-CAT 2 in Table I and compare pFOS-rifc -CAT II with pFOS-flfc -CAT II(A) and II(C) in Table II ). The negative effect on tk promoter activity of the c-fos sequences located between positions -1300 and -850 is specific, since it do not occurs with the c-fos DNA regions from position -2250 to -1400, -1400 to -1300 or -850 to -720 (see pFOS-r/fc -CAT I, II(A) and II(C) in Tables I and U) or with the vitellogenin ERE DNA (pVYT-tk -CAT in Table I ), and is independent of the site of insertion within the pBL-CAT 2 polylinker and from the orientation respect to the promoter (see pFOS-tk -CAT V + and V-in Table IT ). The possible significance of this finding is discussed below. 
The 5-flanking region of the human c-fos gene comprises an imperfectly palindromic Estrogen Response Element that is functional in HeLa cells
The nucleotide sequence of the estrogen-responsive 5'-flanking region of the human c-fos gene, localized between the two Apa I restriction endonuclease sites at about positions -1300 and -850 (see Figure 1) , was determined and is reported in Figure  3 . Analysis of this sequence reveals two elements homologous to known EREs (overlined in Figure 3 ). The first, localized Table III . The free and bound oligonucleotides were resolved in a low ionic strength, non denaturing 4% polyacrylamide gel and visualized by autoradiography. The bands visible at the bottom of each autoradiograph correspond to the free probe, whereas the bands corresponding to specifically retarded probe are indicated. Where specified, the indicated amounts of unlabelled competitor probe were also added during the binding reaction.
between nucleotides 89 and 101, corresponding approximately to positions -1211 and -1199, is characterized by an imperfect palindrome with a 3 bp spacing between its two halves. The second element, localized between nucleotides 390 and 407 (about -910 to -893), is also an imperfect palindrome but with 8 bp in between. Based on the number of spacing nucleotides, the first element is the site for regulation by the estrogen receptor (ERE), whereas the second element is a potential site for regulation by other members of the nuclear receptors super-family (NRRE). The DNA sequence around and within each of these two palyndromic elements shows another distinctive feature: two sequences, in each case, homologous of the core sequence of AP-1 transcription factors binding sites (38) (39) (40) ; underlined in Figure 3 ). To define the contribution of each of these two potential REs to the stimulation of tk promoter activity by the estrogen receptor, the two c-fos upstream sub-regions, from position -1300 to -1060 (sub-region D) or from position -1059 to -850 (subregion P), were cloned, together or separately, upstream of the tk -CAT gene in pBL-CAT 2, to generate the reporters pFOSflt-CAT V +, V -, VI and VH respectively (Figure 4 top) . The results, representative of multiple transfection experiments performed with these reporters, are reported in Figure 4 (bottom), to show that the upstream region identified previously mediates estrogen induction independently of its orientation respect to the promoter (compare lanes 1 and 2, 3 and 4 and pFOS-r/t-CAT V+ and V-in Table II) . Moreover, the element within subregion D can mediate estrogen induction to the same extent with or without that in sub-region P (compare lanes 5 and 6 with lanes 1 and 2 in Figure 4 and pFOS-flt-CAT VI with pFOS-tk-CAT V in Table II) , whereas this last is only weakly responsive to estrogen (compare lanes 7 and 8 with lanes 1 and 2 in Figure  4 and pFOS-tk-CAT VII with pFOS-flt-CAT V in Table II) .
Oligonucleotides reproducing the sequence of the putative ERE or NRRE from the c-fos gene were synthesized (A and D in Table  HI ) and cloned upstream of the tk -CAT gene, either in single copy (pFOS-ERE 1), in three, head-to-tail, copies (pFOS-ERE 3). When tested for estrogen responsivity (Figure 5) , only the hybrid genes containing multiple copies of the ERE-homologous, imperfectly palindromic element from sub-region D are responsive to estrogen (2.5 to 4.5 fold induction). The fact that only multiple copies of this ERE respond to the estrogen receptor is not surprising, since it is known that imperfectly palyndromic EREs can be un-responsive to the estrogen receptor, but cooperate efficiently with each other when present in multiple copies upstream of test promoters (7, 10; M. Ponglikitmongkol, J. H. White and P. Chambon, personal communication) and that, in general, single copies of oligonucleotides reproducing enhancer elements are much less efficient than multiple copies of the same in activating transcription. Mutation of one of the 5 nucleotides identical to the vitellogenin A2 ERE half palyndrome (oligonucleotide C in Table HI ) results in the complete loss of estrogen responsivity (pFOS-ERE/i 3).
The oligonucleotide D, corresponding to the NRREhomologous element from sub-region P (pFOS-NRRE 3) is, instead, inefficient in mediating a transcriptional response to estrogen, even when present in three copies in the reporter, confirming that the major, functional ERE of the c-fos gene is localized in sub-region D, between about positions -1211 and -1199. 
Activation of the c-fos
The human c-fos gene ERE binds in vitro the estrogen receptor and AP-1 transcription factors
The interaction of the estrogen receptor with the fos ERE was studied in vitro using a gel retardation (band-shift) assay and 32 P-labelled oligonucleotides reproducing the fos sequence between about positions -1221 and -1196 (nucleotides 79 to 104 in Figure 3 ; ds-oligonucleotide A in Table III) as binding probes. As a source of estrogen receptor, HeLa cells were transfected with HEO and whole cell extracts were made from transfected cells exposed for 1 hr to 17/3-estradiol prior to collection. Receptor-free extracts, made from cells transfected with the expression vector pSG5 and treated the same way, were used as a control. The results reported in Figure 6 (top panel) shows that two retarded bands (1 and II) are present when labelled oligonucleotide A is incubated with extracts from HEO-transfected cells (+HE0; lanes 6, 7 and 10), whereas only one retarded band (band II) is found with control extracts (-HE0, lane 5), suggesting that two different complexes can form with this probe under these conditions, one of which (corresponding to band I) is due to the presence of the estrogen receptor. The intensity of band I is variable when extracts from different transfections are used (compare it in lanes 6, 7 and 10), whereas the intensity of band II is more constant (compare it in lanes 5, 6, 7 and 10). The size of the complex corresponding to band I is identical to that of the complex formed by the estrogen receptor with an oligonucleotide reproducing the vitellogenin ERE (probe ERE in Table IE ; upper band in lane 4 of Figure 6 ). These data suggests that complex I could be due to the estrogen receptor bound to probe A. To further investigate this possibility, two mutants of the ERE-homologous sequence present in this probe were tested: the first has two base changes in the fos ERE-like sequence, within the 5 nucleotides identical to the vitellogenin ERE (probe B), whereas the second (probe C) has only one base change in this sequence and is unresponsive to the estrogen receptor in vivo (see Figure 5 and Table IV) . With either mutant, only the faster-migrating band II is still present (lanes 8, 9 and 11) and excess of unlabelled mutant B oligonucleotide prevents formation of band II but not of band I (lane 21) with labelled probe A. A competition experiment was also performed using increasing concentrations of un-labelled ERE oligonucleotide against a fixed concentration of labelled probe A and the result shows that the ERE probe competes efficiently for band I but not for band II (lanes 18 to 20) , demonstrating that the complex corresponding to band I is due to estrogen receptor bound to the fos probe. Comparison of the amount of ERE oligonucleotide required for reducing by about 50% the intensity of band I and the amount of A oligonucleotide required to achieve the same result, shows that the relative affinity of the receptor for the/ay ERE is about 1/8 to 1/10 of that for the vitellogenin ERE (compare lanes 12 and 13 with lanes 19 and 20) . This result was confirmed using radioactive ERE and cold A probes (data not shown). Analysis of the sequence present in probe A revealed two areas of homology with the core sequence of AP-1 transcription factors binding sites (underlined in Table HI 1 and 2) . Moreover, a careful examination of band II allows to distinguish two, closely spaced, bands of different intensity (marked with two small arrows in Figure 6 and better visible in lane 2). These data are in agreement with previously published results that suggests that recognition by this transcriptional regulator of its cognate DNA element 'in vitro' do not have a strict sequence requirement and that different AP-ls can interact with variants of this sequence (42 -43 and references therein). This could explain the fact that single mutations within each of the two AP-1-like sequences (as in oligonucleotide C), or a double mutation within one of these sequences (as in oligonucleotide B) do not prevent completely formation of the retarded band II with the fos derived oligonucleotide (lanes 8, 9 and 11).
The lower panel in Figure 6 shows also the results of gel retardation analysis of the complexes formed with the NRREhomologous sequence from sub-region P (oligonucleotides D in Table HI 1, 2 and 3) .
DISCUSSION
Estrogen is a mitogen for target cells of female reproductive organs, where it stimulates transcription of the proto-oncogene c-fos , followed by DNA synthesis and cell proliferation (22 and references therein). We now present evidence that the transcriptional effect of the hormone is, at least in part, due to direct interaction of the estrogen-receptor complex with a regulatory element of c-fos . This is supported by the following evidences: a) it can be reproduced in vitro using the fos promoter and cloned estrogen receptor; b) it is mediated by an ERE localized within the 5'-flanking region of this gene, between about positions -1221 and -1196, that has enhancer characteristics since it confers estrogen responsivity to an heterologous promoter irrespective of its distance and orientation; c) the ERE binds the estrogen receptor in vitro; d) mutations within the ERE that abolish binding of the receptor in vitro prevent transcriptional activation by estrogen in vivo; e) mutants of the human estrogen receptor that lack the DNA Binding Domain fail to activate transcription of this gene. The fos ERE is an imperfectly palyndromic element, different from the perfectly palindromic ERE of the X. laevis vitellogenin A2 gene in that it requires about 10 times more receptor (HE0) to activate transcription in vivo and binds 8 to 10 times less strongly the estrogen receptor in vitro, showing also a lower transcriptional response to the hormone. A similar observation was made with the human pS2 gene ERE, also imperfectly palindromic and less sensitive to the receptor in transfection experiments (9, 37) . The presence of a low affinity ERE regulating the fos gene is probably related to the type of transcriptional response to estrogen that is required in this case. In fact, the response of c-fos to estrogen stimulation differs from that of other estrogen-responsive genes, hi rat uterus, in the presence of continous estrogenic stimulus after a first increase in transcription, during the early Gl phase of the cell cycle, the gene become refractory to the hormone (24) . At the same time, the concentration of transcriptionally active estrogenreceptor complexes increases within the first 2 hrs and than decreases, to a level that is about 1/4 of the peak level (44) . This could result in the dissociation of the weakly bound receptor from the c-fos ERE, with the consequent reduction of transcription of the gene.
Functional analysis of imperfectly palindromic EREs have shown that often they are virtually inactive in isolation, but they can synergize with each other (7, 10) or with other enhancer factors, like for example JUN and AP-1 in the case of the pS2 gene (45) . The fos region that includes the ERE shows two areas of homology with the core sequence of AP-1 transcription factors binding sites, one of which overlaps with the ERE, and oligonucleotides reproducing these sequences binds in vitro AP-1 factors. AP-1 is a composite transcription factor, that can be formed by a repertoire of protein complexes including also FOS, JUN-C and JUN-B (43, 46) . We have shown that also c-jun and jun -B gene transcription is rapidly and transiently stimulated by estrogen in rat uterus at the same time of c-fos (22 and M. Scalona, E. Persico, L. Cicatiello, V. Sica, F. Bresciani and A.
Weisz, manuscript in preparation). Since FOS and JUN-C, separately or in combination with each other, are able to bring about transcriptional activation and transcriptional repression of c-fos gene promoter activity (46 and references therein; 47), and JUN-B can be a transcriptionaJ repressor (48) (49) , one can postulate that the AP-1 binding sites identified near and within the ./ay ERE are involved, perhaps all and with opposite effects, in the regulation of transcription of this gene by estrogen. The interaction of multiple factors, having opposite transcriptionaJ effects, with this ERE is the probable explanation for the relatively low level of induction observed in transfection experiments (this work) and in vivo (21, 24) , since the overall induction depends on the equilibrium reached between the different factors and, in the transfection experiments reported, cellular AP-1 could quench the stimulatory effect of the transfected estrogen receptor on its Response Element. Schule et al. (50) have recently described a similar antagonism between the vitamin D or the retinoic acid receptors and AP-1 on the human osteocalcin gene NRRE. The fos upstream region includes also a putative NRRE, that is unresponsive to the estrogen receptor but that could be recognized by other members of the nuclear receptors super-family (retinoic acid, vitamin D and thyroid hormone receptors). In support of this possibility, vitamin D 3 was found to induce rapidly (within 3 minutes) and transiently c-fos gene transcription in U937 and HL-60 cells (51) ; also, during retinoic acid-induced differentiation of P19 and HL-60 cells, expression of the fos gene is increased (52) (53) .
The basal activity of both/ay and tk promoters is reduced by element(s) present within the -1300 to -850 region of the human c-fos gene. This effect is independent of the distance and of the orientation respect to the promoter, suggesting that it could be the result of the interaction of negative-acting factoids), present in HeLa cells, with regulatory element(s) of the c-/ay gene upstream region. These negative acting element(s) cannot be clearly mapped in one of the two sub-regions D and P defined above, since both sub-regions exert the same effect on the activity of the tk promoter. Comparison of the sequence of the two subregions have revealed two distinct features: the high GC content (71 % and 65% respectively) and the presence of AP-1 binding sites. A human factor, GCF, that binds to GC-rich sequences and represses transcription, have been identified and cloned (54) and is a possible candidate for trans -repression of the reporters containing these fos upstream sequences. For the reasons stated above, more important could be the fact that AP-1 binds to these regions, since this factor, at least in one of its molecular forms (that includes JUN-B), could mediate the transcriptional repression.
In conclusion, upstream of the human c-fos gene we have identified a functional ERE that could account for induction of transcription of this gene by estrogen during the early phases of the cell cycle and, perhaps, in other instances. This ERE is located within a newly identified regulatory region that includes different elements responsive to nuclear receptors, to AP-1 and possibly to other /ra/iy-acting factors.
